Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Irbesartan and Atorvastatin Coadministration
NCT01442987Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of irbesartan and atorvastatin in hypertension (HTN) and hyperlipidemia (6 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Percent change in LDL-Cholesterol at 8 weeks and Change in Blood Pressure at 8 weeks. Started May 2011; status: completed.
02
Drugs
irbesartanatorvastatin
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT01442987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01442987.